INT124447

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.45
First Reported 2005
Last Reported 2005
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 0.86
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Crp)
Anatomy Link Frequency
heart 2
Crp (Mus musculus)
Pain Link Frequency Relevance Heat
Angina 6 50.00 Quite Low
Inflammation 2 50.00 Quite Low
cytokine 1 50.00 Quite Low
Bile 9 5.00 Very Low Very Low Very Low
withdrawal 3 5.00 Very Low Very Low Very Low
peptic ulcer disease 3 5.00 Very Low Very Low Very Low
abdominal pain 2 5.00 Very Low Very Low Very Low
nud 2 5.00 Very Low Very Low Very Low
aspirin 1 5.00 Very Low Very Low Very Low
depression 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disorder Of Lipid Metabolism 48 100.00 Very High Very High Very High
Dyslipidemia /

Combined Dyslipidemia

10 91.68 High High
Cv General 3 Under Development 6 86.96 High High
Necrosis 1 70.04 Quite High
INFLAMMATION 3 50.00 Quite Low
Pancreatitis 1 41.28 Quite Low
Hypertriglyceridemia 8 35.84 Quite Low
Muscle Disease 9 31.76 Quite Low
Coronary Artery Disease 28 5.00 Very Low Very Low Very Low
Increased Venous Pressure Under Development 9 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
RESULTS: Both doses of Xuezhikang induced significant reductions in median CRP levels and in mean CRP levels at day 1 (13.0% with 1200 and 16.6% with 2400 mg/day; 14.7% with 1200 and 18.4% with 2400 mg/day), and at day 7 (18.3% with 1200 and 20.2% with 2400 mg/day; 18.5% with 1200 and 22.6% with 2400 mg/day) as well as at day 14 (28.6% with 1200 and 30.4% with 2400 mg/day; 21.7% with 1200 and 24.8% with 2400 mg/day) compared with baseline without a dose-dependent effect but a time-dependent manner.
Positive_regulation (induced) of Negative_regulation (reductions) of CRP
1) Confidence 0.45 Published 2005 Journal Clin. Chim. Acta Section Body Doc Link 15653117 Disease Relevance 0.17 Pain Relevance 0
CONCLUSION: The result suggested that PCI could lead to a detectable increase in serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could significantly decrease the serum levels of CRP, TNFalpha and cTnI in patients with coronary heart disease; Fluvastatin could also decrease the serum levels of CRP, TNFalpha and cTnI in patients with PCI.


Positive_regulation (increase) of Negative_regulation (levels) of CRP in heart
2) Confidence 0.28 Published 2005 Journal Zhonghua Xin Xue Guan Bing Za Zhi Section Body Doc Link 15932660 Disease Relevance 0.14 Pain Relevance 0
Additionally, ezetimibe/simvastatin produced a significantly greater increase in HDL-C levels and comparable reductions in triglycerides and CRP compared with atorvastatin.
Positive_regulation (increase) of Negative_regulation (reductions) of CRP associated with disorder of lipid metabolism
3) Confidence 0.03 Published 2005 Journal Vascular Health and Risk Management Section Body Doc Link PMC1993967 Disease Relevance 0.41 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox